Patents by Inventor Pier Paolo Pandolfi

Pier Paolo Pandolfi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Micro-RNA and obesity
    Patent number: 11753639
    Abstract: The present disclosure provides a method of treating or preventing metabolic disorders by administering agents that inhibit the activity of microRNAs that modulate metabolism.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: September 12, 2023
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Pier Paolo Pandolfi, Riccardo Panella
  • INHIBITORS OF MICRO-RNA 22
    Publication number: 20230181613
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Application
    Filed: October 12, 2022
    Publication date: June 15, 2023
    Inventors: Pier Paolo PANDOLFI, Riccardo PANELLA, Sakari KAUPPINEN, Andreas PETRI
  • METHODS FOR DUAL DNA/PROTEIN TAGGING OF OPEN CHROMATIN
    Publication number: 20230024461
    Abstract: The invention provides methods, compositions, and kits for characterizing open chromatin by dual DNA/protein tagging.
    Type: Application
    Filed: December 2, 2020
    Publication date: January 26, 2023
    Inventors: Jonathan LEE, Sean CLOHESSY, Pier Paolo PANDOLFI
  • Inhibitors of micro-RNA 22
    Patent number: 11499152
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 15, 2022
    Assignees: Beth Israel Deaconess Medical Center, Aalborg University
    Inventors: Pier Paolo Pandolfi, Riccardo Panella, Sakari Kauppinen, Andreas Petri
  • Micro-RNA inhibitors and their uses in disease
    Patent number: 11274301
    Abstract: The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs).
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: March 15, 2022
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena
  • COMPOSITIONS AND METHODS FOR TREATING A TUMOR SUPPRESSOR DEFICIENT CANCER
    Publication number: 20210301349
    Abstract: As described below, the present invention features compositions and methods of treating cancers characterized by the loss of Pten, Zbtb7a/Pokemon, p53, Pml and other tumor suppressors by inhibiting the expression or activity of CXCL5; and methods for identifying therapeutics using a murine platform.
    Type: Application
    Filed: August 29, 2017
    Publication date: September 30, 2021
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventor: PIER PAOLO PANDOLFI
  • COMPOSITIONS AND METHODS FOR TREATING A TUMOR SUPPRESSOR DEFICIENT CANCER
    Publication number: 20210277102
    Abstract: As described below, the present invention features compositions and methods of treating cancers characterized by the loss of Pten, Zbtb7a/Pokemon, p53, Pml and other tumor suppressors by inhibiting the expression or activity of CXCL17; and methods for identifying CXCL17 antagonists using a murine platform.
    Type: Application
    Filed: August 29, 2017
    Publication date: September 9, 2021
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventor: PIER PAOLO PANDOLFI
  • MICRO-RNA AND OBESITY
    Publication number: 20210017520
    Abstract: The present disclosure provides a method of treating or preventing metabolic disorders by administering agents that inhibit the activity of microRNAs that modulate metabolism.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 21, 2021
    Inventors: Pier Paolo PANDOLFI, Riccardo PANELLA
  • INHIBITORS OF MICRO-RNA 22
    Publication number: 20210017521
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 21, 2021
    Inventors: Pier Paolo PANDOLFI, Riccardo PANELLA, Sakari KAUPPINEN, Andreas PETRI
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20210002649
    Abstract: The invention generally provides a method of treating cancer, the method comprising administering to a subject having a cancer, an effective amount of an agent that inhibits the expression or activity of WW domain-containing protein-1 (WWP1) in combination with anti-PD-1 and/or anti-PD-L1 monoclonal antibodies.
    Type: Application
    Filed: February 28, 2019
    Publication date: January 7, 2021
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Wenyi Wei, Pier Paolo Pandolfi, Yu Ru Lee
  • COMPOUNDS THAT TARGET MYC microRNA RESPONSIVE ELEMENTS FOR THE TREATMENT OF MYC-ASSOCIATED CANCER
    Publication number: 20200140859
    Abstract: Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.
    Type: Application
    Filed: September 4, 2019
    Publication date: May 7, 2020
    Inventors: Pier Paolo Pandolfi, Assaf C. Bester, Yvonne Tay
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20190374506
    Abstract: In some embodiments, the present invention provides a method of treating cancer, the method comprising administering to a subject having a cancer, an effective amount an agent that inhibits the expression or activity of neural precursor cell expressed developmentally down-regulated protein 4 (NEDD4), and an agent that inhibits the expression or activity of WW domain-containing protein-1 (WWP1).
    Type: Application
    Filed: August 29, 2017
    Publication date: December 12, 2019
    Applicant: BETH ISREAL DEACONESS MEDICAL CENTER
    Inventors: YU-RU LEE, PIER PAOLO PANDOLFI
  • Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
    Patent number: 10443055
    Abstract: Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: October 15, 2019
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Pier Paolo Pandolfi, Assaf C. Bester, Yvonne Tay
  • Micro-RNA inhibitors and their uses in disease
    Patent number: 10131905
    Abstract: The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oliognucleotides, including locked nucleic acids (LNAs).
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: November 20, 2018
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena
  • COMPOUNDS THAT TARGET MYC microRNA RESPONSIVE ELEMENTS FOR THE TREATMENT OF MYC-ASSOCIATED CANCER
    Publication number: 20180195067
    Abstract: Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.
    Type: Application
    Filed: December 18, 2017
    Publication date: July 12, 2018
    Inventors: Pier Paolo Pandolfi, Assaf C. Bester, Yvonne Tay
  • Treatment of Cancers with Micro-RNA Inhibitors
    Publication number: 20180105813
    Abstract: The invention relates to the treatment and prevention of cancers, including blood-based cancers and breast cancers, by administering agents that inhibit the activity of microRNAs, including miR-22. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs).
    Type: Application
    Filed: October 4, 2017
    Publication date: April 19, 2018
    Inventors: Pier Paolo Pandolfi, Sujung Song
  • Micro-RNA Inhibitors and Their Uses in Disease
    Publication number: 20180073025
    Abstract: The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oliognucleotides, including locked nucleic acids (LNAs).
    Type: Application
    Filed: October 6, 2017
    Publication date: March 15, 2018
    Inventors: Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena
  • Treatment of cancers with micro-RNA inhibitors
    Patent number: 9822358
    Abstract: The invention relates to the treatment and prevention of cancers, including blood-based cancers and breast cancers, by administering agents that inhibit the activity of microRNAs, including miR-22. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs).
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: November 21, 2017
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Pier Paolo Pandolfi, Sujung Song
  • NOVEL FUSION-CIRCULAR RNAs AND USES THEREOF
    Publication number: 20170298347
    Abstract: Novel fusion-circular RNAs (f-circRNAs) and complements thereof are provided. Diagnostic and treatment methods using f-circRNA inhibitors are provided. Non-human animals expressing exogenous f-circRNA and complements thereof are also provided.
    Type: Application
    Filed: January 27, 2017
    Publication date: October 19, 2017
    Inventors: Pier Paolo Pandolfi, Jlenia Guarnerio
  • MICRO-RNA INHIBITORS AND THEIR USES IN DISEASE
    Publication number: 20150126579
    Abstract: The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oliognucleotides, including locked nucleic acids (LNAs).
    Type: Application
    Filed: April 12, 2012
    Publication date: May 7, 2015
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena